Efficacy News and Research

RSS

New class of drugs reduces adverse effects of cellular damage from cancer chemotherapy

Chemotherapy kills tumor cells, but it also wreaks havoc on the rest of the body. A team of researchers led by Igor Roninson of the South Carolina College of Pharmacy just reported the discovery of a new class of drugs that reduces the adverse effects of cellular damage from chemotherapy.

8 Aug 2012

Corticosteroids show no clinical benefit in treating acute sinusitis

Corticosteroids, frequently prescribed to alleviate acute sinusitis, show no clinical benefit in treating the condition, according to a randomized controlled trial published in CMAJ.

8 Aug 2012

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

A pivotal clinical trial for an anti-rabies human monoclonal antibody (RMAb) being developed through a collaborative partnership between MassBiologics of the University of Massachusetts Medical School and the Serum Institute of India, Ltd., is starting to enroll patients.

8 Aug 2012

Pets may trigger ‘prosocial’ behavior in autistic children

Autistic children show improvements in certain aspects of prosocial behavior after the introduction of pets into the family home, researchers report.

7 Aug 2012

NYUCN professor to investigate efficacy of Acu/Moxa in managing irritable bowel syndrome

New York University College of Nursing's (NYUCN) Joyce K. Anastasi, PhD, DrNP, FAAN, LAc., the Independence Foundation Endowed Professor and Founding Director of the Division of Special Studies in Symptom Management at NYUCN has been awarded a $2.5 million four-year National Institutes of Health (NIH) grant for the study of "Symptom management for irritable bowel syndrome (IBS) constipation".

7 Aug 2012

Scientists discover biological marker that may help identify patients’ response to antidepressants

Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say National Institutes of Health researchers.

7 Aug 2012

Blood levels of IL-6 protein may also serve as red flag for relapse in schizophrenia patients

Blood levels of a protein that helps regulate inflammation may also serve as a red flag for relapse in some schizophrenia patients, researchers said.

7 Aug 2012

Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG.

7 Aug 2012

Commercial cattle vaccine can effectively reduce levels of E. coli by more than 50%

A commercial vaccine for cattle can effectively reduce levels of E. coli by more than 50 percent, a Kansas State University study has found. The vaccine is also effective using two doses instead of the recommended three doses, which can help cut costs for the beef industry.

7 Aug 2012

Scripps Florida scientists to identify and develop new therapeutic approaches against cancers

Scientists from the Florida campus of The Scripps Research Institute have been awarded approximately $1.5 million from the National Institutes of Health to identify and develop new therapeutic approaches against a broad spectrum of cancers.

7 Aug 2012

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

6 Aug 2012

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

TWi Pharmaceuticals, Inc., a specialty pharmaceutical company based in Taiwan, today announced its fully owned subsidiary, TWi Biotechnology, Inc. has completed a multinational phase II dose-ranging study of AC-201, an orally available IL-1 Beta modulator, in 259 patients with type II diabetes uncontrolled on up to three oral medications.

6 Aug 2012

Genocea announces new data that supports novel approach for development of HSV-2 vaccine

Genocea Biosciences announced today the presentation of new data supporting its novel approach to developing a first-in-class, protein subunit therapeutic vaccine for Herpes Simplex Virus type 2 (HSV-2).

6 Aug 2012

Potential new drug to treat common inherited kidney disease

Scientists at UC Santa Barbara have demonstrated in the laboratory that a new drug is effective in treating a very common kidney disease -- although it will be a few years before it becomes available for clinical testing. The findings resulted from a collaboration between UCSB and a biotech firm based in Indiana. The study is published in this week's Journal of the American Society of Nephrology.

3 Aug 2012

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

The once-daily integrase inhibitor dolutegravir has shown promise in a phase III noninferiority study comparing it with twice-daily raltegravir for treatment of HIV-1, indicate study results presented at the 19th International AIDS Conference in Washington DC, USA.

3 Aug 2012

SAGE Labs, Autism Speaks expand partnership to create first rat models for translational research

Autism Speaks, the world's leading autism science and advocacy organization, today announced its expanded collaboration with Sigma Advanced Genetic Engineering (SAGE) Labs, an initiative of Sigma- Life, to develop the first rat models with modified autism associated genes, intended to accelerate discovery and translational autism research.

3 Aug 2012

Healthpoint Biotherapeutics announces results from HP802-247 Phase 2b trial on venous leg ulcers

Healthpoint Biotherapeutics today announced that the results for its Phase 2b clinical trial investigating the efficacy of HP802-247 in venous leg ulcers is published on The Lancet, beginning August 3, 2012, with Online First access to the article, followed by print publication in the next issue.

3 Aug 2012

New FDA risk management plan aims to reduce opioid abuse in the U.S.

A new risk management plan from the U.S. Food and Drug Administration to help clinicians properly prescribe drugs with addiction potential aims to help reduce the growing epidemic of opioid abuse in the United States.

2 Aug 2012

Researchers develop bioactive coating that actively suppresses brain's immune response

Brain-computer interfaces are at the cutting edge for treatment of neurological and psychological disorder, including Parkinson's, epilepsy, and depression. Among the most promising advance is deep brain stimulation (DBS) - a method in which a silicon chip implanted under the skin ejects high frequency currents that are transferred to the brain through implanted electrodes that transmit and receive the signals.

1 Aug 2012

Shampoo effective for pruritus relief in dogs

Shampooing dogs with pruritus is an effective method to reduce symptoms even if the shampoo does not contain any active ingredients, report researchers in Veterinary Record.

1 Aug 2012

Efficacy News and Research

New class of drugs reduces adverse effects of cellular damage from cancer chemotherapy

Corticosteroids show no clinical benefit in treating acute sinusitis

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

Pets may trigger ‘prosocial’ behavior in autistic children

NYUCN professor to investigate efficacy of Acu/Moxa in managing irritable bowel syndrome

Scientists discover biological marker that may help identify patients’ response to antidepressants

Blood levels of IL-6 protein may also serve as red flag for relapse in schizophrenia patients

Novartis’ pasireotide offers symptom relief for patients with advanced neuroendocrine tumors

Commercial cattle vaccine can effectively reduce levels of E. coli by more than 50%

Scripps Florida scientists to identify and develop new therapeutic approaches against cancers

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

Genocea announces new data that supports novel approach for development of HSV-2 vaccine

Potential new drug to treat common inherited kidney disease

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

SAGE Labs, Autism Speaks expand partnership to create first rat models for translational research

Healthpoint Biotherapeutics announces results from HP802-247 Phase 2b trial on venous leg ulcers

New FDA risk management plan aims to reduce opioid abuse in the U.S.

Researchers develop bioactive coating that actively suppresses brain's immune response

Shampoo effective for pruritus relief in dogs

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News